Ensign Peak Advisors Inc boosted its stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by 20.7% during the second quarter, Holdings Channel.com reports. The firm owned 79,461 shares of the company’s stock after buying an additional 13,653 shares during the period. Ensign Peak Advisors Inc’s holdings in Biohaven Pharmaceutical were worth $7,714,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the business. Marshall Wace LLP bought a new stake in shares of Biohaven Pharmaceutical during the first quarter valued at approximately $365,000. Envestnet Asset Management Inc. lifted its holdings in shares of Biohaven Pharmaceutical by 28.8% during the first quarter. Envestnet Asset Management Inc. now owns 3,469 shares of the company’s stock valued at $237,000 after purchasing an additional 776 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Biohaven Pharmaceutical by 22.8% during the first quarter. Teacher Retirement System of Texas now owns 5,597 shares of the company’s stock valued at $383,000 after purchasing an additional 1,039 shares in the last quarter. UBS Group AG increased its position in Biohaven Pharmaceutical by 8.0% during the first quarter. UBS Group AG now owns 39,360 shares of the company’s stock valued at $2,690,000 after acquiring an additional 2,900 shares during the last quarter. Finally, E Fund Management Co. Ltd. purchased a new stake in Biohaven Pharmaceutical during the first quarter valued at $116,000. 92.14% of the stock is currently owned by institutional investors and hedge funds.
BHVN has been the subject of a number of analyst reports. UBS Group cut Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating and upped their price target for the stock from $108.00 to $109.00 in a research report on Tuesday, August 10th. HC Wainwright reiterated a “buy” rating and issued a $160.00 price target (up from $135.00) on shares of Biohaven Pharmaceutical in a report on Wednesday, October 6th. SVB Leerink restated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Thursday, October 7th. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “strong sell” rating to a “hold” rating and set a $123.00 price target on the stock in a report on Monday, July 12th. Finally, Mizuho reissued a “buy” rating and issued a $137.00 price objective on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 5th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $137.45.
Biohaven Pharmaceutical (NYSE:BHVN) last released its earnings results on Sunday, August 8th. The company reported ($3.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.77) by ($0.46). The firm had revenue of $92.93 million for the quarter, compared to the consensus estimate of $85.85 million. During the same period in the prior year, the firm earned ($2.55) earnings per share. The business’s revenue was up 858.3% on a year-over-year basis. Sell-side analysts forecast that Biohaven Pharmaceutical Holding Company Ltd. will post -11.73 EPS for the current year.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.
Featured Story: What is the operating income formula?
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN).
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.